SCHEMBL3281600

SCHEMBL3281600

O=C(NCC(=O)N1CCN(CCCN2CCOCC2)CC1)c1ccc(S(=O)(=O)N(Oc2ccc(Cl)cc2Cl)c2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
TDP1 Q9NUW8 1/20 0.45
CA12 O43570 2/20 0.43
CA9 Q16790 2/20 0.43
GAA P10253 2/20 0.42
KMT2A Q03164 1/20 0.41
HTR1A P08908 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
KCNH2 Q12809 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
CA1 P00915 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15103873 0.98 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2TDP1CA12CA9
SCHEMBL3274385 0.97 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2TDP1CA12CA9
SCHEMBL3275589 0.93 PSEN1 (0.43) SMN1; SMN2LMNA
SCHEMBL3273929 0.93 PSEN1 (0.43) SMN1; SMN2CA12CA9KMT2A
SCHEMBL15103806 0.93 KMT2A (0.45) ALDH1A1SMN1; SMN2GAAKMT2AKDM4E
SCHEMBL15103760 0.92 L3MBTL1 (0.42) ALDH1A1SMN1; SMN2TDP1GAAKMT2A
SCHEMBL3280575 0.92 PSEN1 (0.42) SMN1; SMN2NPSR1
SCHEMBL3274097 0.92 CCR2 (0.42) ALDH1A1SMN1; SMN2CA12CA9KMT2A
SCHEMBL3275533 0.91 CCR2 (0.44) SMN1; SMN2CA12CA9GAAKMT2A
SCHEMBL3274320 0.90 KMT2A (0.41) ALDH1A1SMN1; SMN2TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP claimed
US-8481527-B2 Benzamide derivatives as bradykinin antagonists RICHTER GEDEON NYRT. (HU) 2013-07-09 US claimed
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-08 US claimed
EP-2076491-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-08 EP claimed
WO-2008068540-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-06-12 WO claimed
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 ALDH1A1 2842/4885SMN1; SMN2 4508/4885TDP1 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.